ImmunoPrecise Antibodies Ltd.

How big is ImmunoPrecise Antibodies Ltd.?

As of Jun 18, ImmunoPrecise Antibodies Ltd. has a market capitalization of 43.31 million and reported net sales of 17.42 million with a net profit of -33.23 million over the latest four quarters.

Market Cap: As of Jun 18, ImmunoPrecise Antibodies Ltd. has a market capitalization of 43.31 million, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 17.42 million and a net profit of -33.23 million.<BR><BR>Balance Sheet Snapshot: As of Apr 24, the shareholder's funds were 24.69 million, and total assets amounted to 43.66 million.

What does ImmunoPrecise Antibodies Ltd. do?

ImmunoPrecise Antibodies Ltd. is a Canadian micro-cap company specializing in custom hybridoma development services for the Pharmaceuticals & Biotechnology industry. As of January 2025, it reported net sales of $4 million and a net loss of $15 million, with a market cap of $43.31 million.

Overview: <BR>ImmunoPrecise Antibodies Ltd. is a Canada-based supplier of custom hybridoma development services in the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 4 Million (Quarterly Results - Jan 2025) <BR>Most recent Net Profit: -15 Million (Quarterly Results - Jan 2025) <BR>Market cap: USD 43.31 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.45 <BR>Return on Equity: -41.78% <BR>Price to Book: 2.50<BR><BR>Contact Details: <BR>Address: 880 - 580 HORNBY STREET, VANCOUVER BC : V6C3B6 <BR>Tel: ['1 604 8060626', '1 438 8637071'] <BR>Fax: 1 250 4830309 <BR>Website: https://immunoprecise.com/

Should I buy, sell or hold ImmunoPrecise Antibodies Ltd.?

Who are in the management team of ImmunoPrecise Antibodies Ltd.?

As of March 2022, the management team of ImmunoPrecise Antibodies Ltd. includes Independent Chairman Mr. James Kuo, President and CEO Ms. Jennifer Bath, and several Independent Directors: Mr. Paul Andreola, Mr. Robert Beecroft, Mr. Robert Burke, Mr. Brian Lundstrom, and Mr. Greg Smith.

As of March 2022, the management team of ImmunoPrecise Antibodies Ltd. includes the following individuals:<BR><BR>- Mr. James Kuo, who serves as the Independent Chairman of the Board.<BR>- Ms. Jennifer Bath, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Paul Andreola, who is an Independent Director.<BR>- Mr. Robert Beecroft, who is also an Independent Director.<BR>- Mr. Robert Burke, serving as an Independent Director.<BR>- Mr. Brian Lundstrom, who is an Independent Director.<BR>- Mr. Greg Smith, who is another Independent Director. <BR><BR>This team comprises a mix of leadership roles and independent directors, contributing to the governance of the company.

Is ImmunoPrecise Antibodies Ltd. technically bullish or bearish?

As of September 11, 2025, ImmunoPrecise Antibodies Ltd. shows a bullish technical trend, with strong MACD and KST indicators, despite mixed signals from Dow Theory, and has significantly outperformed the S&P 500 year-to-date.

As of 11 September 2025, the technical trend for ImmunoPrecise Antibodies Ltd. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The Bollinger Bands indicate a mildly bullish stance on both weekly and monthly time frames. The KST is bullish for both weekly and monthly periods. However, the Dow Theory shows a mildly bearish signal on the weekly chart and a mildly bullish signal on the monthly chart. The daily moving averages are mildly bullish. <BR><BR>In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date with a return of 356.64% compared to the S&P 500's 12.22%, but it has underperformed over the longer three and five-year periods. Overall, the current technical stance is bullish, supported by several key indicators, particularly the MACD and KST.